CA
EW icon

Capitolis Advisors’s Edwards Lifesciences EW Stock Holding History

Capitolis Advisors’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-36,245
Closed -$4.7M – 264
2021
Q4 		$4.7M Buy
36,245
+11,530
+47% +$1.34M 0.03% 320
2021
Q3 		$2.75M Buy
24,715
+13,018
+111% +$1.49M 0.03% 271
2021
Q2 		$1.21M Sell
11,697
-24,526
-68% -$2.31M 0.01% 291
2021
Q1 		$3.03M Hold
36,223
– – 0.05% 213
2020
Q4 		$3.31M Buy
+36,223
New +$3M 0.06% 252

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capitolis Advisors's EW Position: Q1 2022 in Review

Capitolis Advisors sold out of Edwards Lifesciences (EW) in Q1 2022, closing a stake of 36,245 shares — an estimated $4.7M sold.

Capitolis Advisors first reported a position in EW in Q4 2020 and held it in 5 quarters. The position peaked at $4.7M in Q4 2021. 1,312 funds tracked by Wall St. Rank hold EW as of Q1 2022.

  • Capitolis Advisors reported no remaining Edwards Lifesciences position as of Q1 2022 after selling out during the quarter.
  • Capitolis Advisors sold 36,245 Edwards Lifesciences shares in Q1 2022, an estimated $4.7M.
  • Capitolis Advisors first reported a position in Edwards Lifesciences in Q4 2020 and held it in 5 quarters.
  • Capitolis Advisors's Edwards Lifesciences position peaked at $4.7M in Q4 2021.
  • 1,312 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2022.

Based on Capitolis Advisors's 13F filing for Q1 2022, filed 12 May 2022.